nodes	percent_of_prediction	percent_of_DWPC	metapath
Methadone—CYP1A2—Imiquimod—skin cancer	0.0886	0.108	CbGbCtD
Methadone—CYP2C8—Vismodegib—skin cancer	0.0793	0.0964	CbGbCtD
Methadone—CYP2C19—Vismodegib—skin cancer	0.0665	0.0809	CbGbCtD
Methadone—CYP2C9—Vismodegib—skin cancer	0.0553	0.0672	CbGbCtD
Methadone—ABCB1—Vismodegib—skin cancer	0.0537	0.0653	CbGbCtD
Methadone—CYP1A2—Vemurafenib—skin cancer	0.0485	0.059	CbGbCtD
Methadone—CYP3A4—Imiquimod—skin cancer	0.0464	0.0564	CbGbCtD
Methadone—CYP3A4—Temozolomide—skin cancer	0.0464	0.0564	CbGbCtD
Methadone—CYP2D6—Vemurafenib—skin cancer	0.04	0.0486	CbGbCtD
Methadone—CYP1A2—Dacarbazine—skin cancer	0.0372	0.0452	CbGbCtD
Methadone—CYP3A4—Vismodegib—skin cancer	0.0322	0.0391	CbGbCtD
Methadone—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0298	0.0363	CbGbCtD
Methadone—CYP3A7—Docetaxel—skin cancer	0.0298	0.0363	CbGbCtD
Methadone—ABCB1—Dactinomycin—skin cancer	0.0282	0.0343	CbGbCtD
Methadone—CYP2C8—Fluorouracil—skin cancer	0.0282	0.0342	CbGbCtD
Methadone—CYP3A4—Vemurafenib—skin cancer	0.0254	0.0309	CbGbCtD
Methadone—CYP3A5—Docetaxel—skin cancer	0.0224	0.0272	CbGbCtD
Methadone—CYP1A2—Fluorouracil—skin cancer	0.0218	0.0265	CbGbCtD
Methadone—CYP2C9—Fluorouracil—skin cancer	0.0196	0.0239	CbGbCtD
Methadone—ABCB1—Docetaxel—skin cancer	0.0146	0.0177	CbGbCtD
Methadone—CYP3A4—Docetaxel—skin cancer	0.00872	0.0106	CbGbCtD
Methadone—CHRNA10—ear—skin cancer	0.00665	0.281	CbGeAlD
Methadone—HTR3A—nerve—skin cancer	0.00194	0.0819	CbGeAlD
Methadone—OPRM1—nerve—skin cancer	0.00178	0.0751	CbGeAlD
Methadone—Lacrimation—Fluorouracil—skin cancer	0.00177	0.0116	CcSEcCtD
Methadone—Pulmonary oedema—Imiquimod—skin cancer	0.00168	0.011	CcSEcCtD
Methadone—Lung disorder—Temozolomide—skin cancer	0.0016	0.0104	CcSEcCtD
Methadone—Swelling—Imiquimod—skin cancer	0.00155	0.0101	CcSEcCtD
Methadone—Muscle spasms—Vismodegib—skin cancer	0.0015	0.00983	CcSEcCtD
Methadone—Cardiac failure—Imiquimod—skin cancer	0.0014	0.00916	CcSEcCtD
Methadone—Irritability—Imiquimod—skin cancer	0.00131	0.00854	CcSEcCtD
Methadone—Urinary retention—Imiquimod—skin cancer	0.0013	0.0085	CcSEcCtD
Methadone—Amenorrhoea—Temozolomide—skin cancer	0.00129	0.0084	CcSEcCtD
Methadone—Lacrimation—Docetaxel—skin cancer	0.00128	0.00835	CcSEcCtD
Methadone—Weight decreased—Vemurafenib—skin cancer	0.00126	0.0082	CcSEcCtD
Methadone—CHRNA10—lymphoid tissue—skin cancer	0.00123	0.0521	CbGeAlD
Methadone—Sweating increased—Imiquimod—skin cancer	0.00115	0.00753	CcSEcCtD
Methadone—Lacrimation increased—Fluorouracil—skin cancer	0.00113	0.00738	CcSEcCtD
Methadone—Phlebitis—Bleomycin—skin cancer	0.00113	0.00738	CcSEcCtD
Methadone—Redness—Docetaxel—skin cancer	0.00111	0.00727	CcSEcCtD
Methadone—Decreased appetite—Vismodegib—skin cancer	0.00111	0.00725	CcSEcCtD
Methadone—Constipation—Vismodegib—skin cancer	0.00109	0.00713	CcSEcCtD
Methadone—Pain—Vismodegib—skin cancer	0.00109	0.00713	CcSEcCtD
Methadone—Disorientation—Bleomycin—skin cancer	0.00109	0.0071	CcSEcCtD
Methadone—Phlebitis—Dactinomycin—skin cancer	0.00105	0.00688	CcSEcCtD
Methadone—Gastrointestinal pain—Vismodegib—skin cancer	0.00104	0.00682	CcSEcCtD
Methadone—Dermatitis contact—Fluorouracil—skin cancer	0.00103	0.00672	CcSEcCtD
Methadone—Abdominal pain—Vismodegib—skin cancer	0.00101	0.0066	CcSEcCtD
Methadone—Chills—Vemurafenib—skin cancer	0.000996	0.00651	CcSEcCtD
Methadone—CHRNA10—head—skin cancer	0.000994	0.042	CbGeAlD
Methadone—Erythema—Vemurafenib—skin cancer	0.000967	0.00632	CcSEcCtD
Methadone—CYP2C18—mammalian vulva—skin cancer	0.000956	0.0404	CbGeAlD
Methadone—Rhinorrhoea—Docetaxel—skin cancer	0.000928	0.00606	CcSEcCtD
Methadone—Asthenia—Vismodegib—skin cancer	0.000916	0.00599	CcSEcCtD
Methadone—Visual impairment—Imiquimod—skin cancer	0.000913	0.00596	CcSEcCtD
Methadone—Pruritus—Vismodegib—skin cancer	0.000904	0.0059	CcSEcCtD
Methadone—Euphoric mood—Fluorouracil—skin cancer	0.000895	0.00585	CcSEcCtD
Methadone—Flushing—Imiquimod—skin cancer	0.000879	0.00574	CcSEcCtD
Methadone—GRIN3A—head—skin cancer	0.000878	0.0371	CbGeAlD
Methadone—Diarrhoea—Vismodegib—skin cancer	0.000874	0.00571	CcSEcCtD
Methadone—Swelling—Fluorouracil—skin cancer	0.000857	0.0056	CcSEcCtD
Methadone—Amenorrhoea—Docetaxel—skin cancer	0.000855	0.00559	CcSEcCtD
Methadone—Chills—Imiquimod—skin cancer	0.00085	0.00555	CcSEcCtD
Methadone—Arrhythmia—Imiquimod—skin cancer	0.000846	0.00553	CcSEcCtD
Methadone—Disorientation—Fluorouracil—skin cancer	0.000845	0.00552	CcSEcCtD
Methadone—Erythema—Imiquimod—skin cancer	0.000824	0.00539	CcSEcCtD
Methadone—Lacrimation increased—Docetaxel—skin cancer	0.000816	0.00533	CcSEcCtD
Methadone—Vomiting—Vismodegib—skin cancer	0.000812	0.0053	CcSEcCtD
Methadone—Drug interaction—Docetaxel—skin cancer	0.00081	0.00529	CcSEcCtD
Methadone—Rash—Vismodegib—skin cancer	0.000805	0.00526	CcSEcCtD
Methadone—Dermatitis—Vismodegib—skin cancer	0.000804	0.00526	CcSEcCtD
Methadone—Anaphylactic shock—Vemurafenib—skin cancer	0.000789	0.00515	CcSEcCtD
Methadone—Cardiac failure—Fluorouracil—skin cancer	0.000775	0.00506	CcSEcCtD
Methadone—Weight decreased—Bleomycin—skin cancer	0.00076	0.00497	CcSEcCtD
Methadone—Nausea—Vismodegib—skin cancer	0.000759	0.00496	CcSEcCtD
Methadone—Agitation—Imiquimod—skin cancer	0.000758	0.00495	CcSEcCtD
Methadone—Hypokalaemia—Temozolomide—skin cancer	0.000747	0.00488	CcSEcCtD
Methadone—Syncope—Imiquimod—skin cancer	0.000739	0.00483	CcSEcCtD
Methadone—Hypotension—Vemurafenib—skin cancer	0.000737	0.00482	CcSEcCtD
Methadone—Palpitations—Imiquimod—skin cancer	0.000729	0.00476	CcSEcCtD
Methadone—Loss of consciousness—Imiquimod—skin cancer	0.000725	0.00473	CcSEcCtD
Methadone—Irritability—Fluorouracil—skin cancer	0.000721	0.00471	CcSEcCtD
Methadone—Cardiac arrest—Fluorouracil—skin cancer	0.000719	0.0047	CcSEcCtD
Methadone—Convulsion—Imiquimod—skin cancer	0.000714	0.00467	CcSEcCtD
Methadone—OPRK1—female reproductive system—skin cancer	0.00071	0.03	CbGeAlD
Methadone—Anxiety—Imiquimod—skin cancer	0.000699	0.00457	CcSEcCtD
Methadone—CHRNA10—lymph node—skin cancer	0.000696	0.0294	CbGeAlD
Methadone—Sweating increased—Temozolomide—skin cancer	0.000691	0.00451	CcSEcCtD
Methadone—Dry mouth—Imiquimod—skin cancer	0.000686	0.00448	CcSEcCtD
Methadone—Decreased appetite—Vemurafenib—skin cancer	0.000686	0.00448	CcSEcCtD
Methadone—Nasopharyngitis—Fluorouracil—skin cancer	0.000676	0.00442	CcSEcCtD
Methadone—Constipation—Vemurafenib—skin cancer	0.000675	0.00441	CcSEcCtD
Methadone—Oedema—Imiquimod—skin cancer	0.000673	0.0044	CcSEcCtD
Methadone—Lightheadedness—Docetaxel—skin cancer	0.000672	0.00439	CcSEcCtD
Methadone—Pulmonary oedema—Docetaxel—skin cancer	0.000669	0.00437	CcSEcCtD
Methadone—Shock—Imiquimod—skin cancer	0.000662	0.00432	CcSEcCtD
Methadone—Tachycardia—Imiquimod—skin cancer	0.000657	0.00429	CcSEcCtD
Methadone—Hyperhidrosis—Imiquimod—skin cancer	0.00065	0.00425	CcSEcCtD
Methadone—Weight increased—Temozolomide—skin cancer	0.000645	0.00422	CcSEcCtD
Methadone—Weight decreased—Temozolomide—skin cancer	0.000642	0.00419	CcSEcCtD
Methadone—Anorexia—Imiquimod—skin cancer	0.000641	0.00419	CcSEcCtD
Methadone—Phlebitis—Docetaxel—skin cancer	0.000633	0.00414	CcSEcCtD
Methadone—Flushing—Bleomycin—skin cancer	0.000624	0.00408	CcSEcCtD
Methadone—Body temperature increased—Vemurafenib—skin cancer	0.000624	0.00407	CcSEcCtD
Methadone—Swelling—Docetaxel—skin cancer	0.000618	0.00404	CcSEcCtD
Methadone—OPRD1—head—skin cancer	0.000618	0.0261	CbGeAlD
Methadone—Insomnia—Imiquimod—skin cancer	0.000609	0.00398	CcSEcCtD
Methadone—Chills—Bleomycin—skin cancer	0.000604	0.00394	CcSEcCtD
Methadone—CYP19A1—connective tissue—skin cancer	0.000601	0.0254	CbGeAlD
Methadone—Somnolence—Imiquimod—skin cancer	0.000598	0.00391	CcSEcCtD
Methadone—OPRK1—head—skin cancer	0.000593	0.025	CbGeAlD
Methadone—Erythema—Bleomycin—skin cancer	0.000586	0.00383	CcSEcCtD
Methadone—Decreased appetite—Imiquimod—skin cancer	0.000585	0.00382	CcSEcCtD
Methadone—Flushing—Dactinomycin—skin cancer	0.000582	0.0038	CcSEcCtD
Methadone—Hypersensitivity—Vemurafenib—skin cancer	0.000581	0.0038	CcSEcCtD
Methadone—Visual disturbance—Docetaxel—skin cancer	0.000576	0.00376	CcSEcCtD
Methadone—Pain—Imiquimod—skin cancer	0.000575	0.00376	CcSEcCtD
Methadone—CYP1A2—nipple—skin cancer	0.000568	0.024	CbGeAlD
Methadone—Asthenia—Vemurafenib—skin cancer	0.000566	0.0037	CcSEcCtD
Methadone—Hallucination—Temozolomide—skin cancer	0.000565	0.00369	CcSEcCtD
Methadone—Chills—Dactinomycin—skin cancer	0.000563	0.00368	CcSEcCtD
Methadone—Cardiac failure—Docetaxel—skin cancer	0.000559	0.00365	CcSEcCtD
Methadone—Pruritus—Vemurafenib—skin cancer	0.000558	0.00365	CcSEcCtD
Methadone—Feeling abnormal—Imiquimod—skin cancer	0.000554	0.00362	CcSEcCtD
Methadone—Gastrointestinal pain—Imiquimod—skin cancer	0.00055	0.00359	CcSEcCtD
Methadone—Visual impairment—Temozolomide—skin cancer	0.000547	0.00357	CcSEcCtD
Methadone—Erythema—Dactinomycin—skin cancer	0.000546	0.00357	CcSEcCtD
Methadone—Diarrhoea—Vemurafenib—skin cancer	0.00054	0.00353	CcSEcCtD
Methadone—Urticaria—Imiquimod—skin cancer	0.000535	0.00349	CcSEcCtD
Methadone—Body temperature increased—Imiquimod—skin cancer	0.000532	0.00347	CcSEcCtD
Methadone—Abdominal pain—Imiquimod—skin cancer	0.000532	0.00347	CcSEcCtD
Methadone—Flushing—Temozolomide—skin cancer	0.000527	0.00344	CcSEcCtD
Methadone—Dizziness—Vemurafenib—skin cancer	0.000522	0.00341	CcSEcCtD
Methadone—Chills—Temozolomide—skin cancer	0.000509	0.00333	CcSEcCtD
Methadone—Vomiting—Vemurafenib—skin cancer	0.000502	0.00328	CcSEcCtD
Methadone—Orthostatic hypotension—Docetaxel—skin cancer	0.000498	0.00326	CcSEcCtD
Methadone—Rash—Vemurafenib—skin cancer	0.000497	0.00325	CcSEcCtD
Methadone—Dermatitis—Vemurafenib—skin cancer	0.000497	0.00325	CcSEcCtD
Methadone—Hypersensitivity—Imiquimod—skin cancer	0.000496	0.00324	CcSEcCtD
Methadone—Headache—Vemurafenib—skin cancer	0.000494	0.00323	CcSEcCtD
Methadone—Erythema—Temozolomide—skin cancer	0.000494	0.00323	CcSEcCtD
Methadone—Nasopharyngitis—Docetaxel—skin cancer	0.000488	0.00319	CcSEcCtD
Methadone—Asthenia—Imiquimod—skin cancer	0.000483	0.00315	CcSEcCtD
Methadone—Confusional state—Bleomycin—skin cancer	0.000482	0.00315	CcSEcCtD
Methadone—Anaphylactic shock—Bleomycin—skin cancer	0.000478	0.00312	CcSEcCtD
Methadone—Oedema—Bleomycin—skin cancer	0.000478	0.00312	CcSEcCtD
Methadone—Pruritus—Imiquimod—skin cancer	0.000476	0.00311	CcSEcCtD
Methadone—Nausea—Vemurafenib—skin cancer	0.000469	0.00306	CcSEcCtD
Methadone—Thrombocytopenia—Bleomycin—skin cancer	0.000468	0.00306	CcSEcCtD
Methadone—Arrhythmia—Fluorouracil—skin cancer	0.000467	0.00305	CcSEcCtD
Methadone—Tremor—Temozolomide—skin cancer	0.000463	0.00302	CcSEcCtD
Methadone—Diarrhoea—Imiquimod—skin cancer	0.00046	0.00301	CcSEcCtD
Methadone—HTR3A—head—skin cancer	0.00046	0.0194	CbGeAlD
Methadone—Anorexia—Bleomycin—skin cancer	0.000456	0.00298	CcSEcCtD
Methadone—Erythema—Fluorouracil—skin cancer	0.000455	0.00297	CcSEcCtD
Methadone—Agitation—Temozolomide—skin cancer	0.000454	0.00297	CcSEcCtD
Methadone—Hypotension—Bleomycin—skin cancer	0.000447	0.00292	CcSEcCtD
Methadone—Oedema—Dactinomycin—skin cancer	0.000446	0.00291	CcSEcCtD
Methadone—Dizziness—Imiquimod—skin cancer	0.000445	0.00291	CcSEcCtD
Methadone—Vertigo—Temozolomide—skin cancer	0.000444	0.0029	CcSEcCtD
Methadone—Palpitations—Temozolomide—skin cancer	0.000437	0.00285	CcSEcCtD
Methadone—Thrombocytopenia—Dactinomycin—skin cancer	0.000437	0.00285	CcSEcCtD
Methadone—Weight increased—Docetaxel—skin cancer	0.000429	0.0028	CcSEcCtD
Methadone—Convulsion—Temozolomide—skin cancer	0.000428	0.0028	CcSEcCtD
Methadone—Vomiting—Imiquimod—skin cancer	0.000428	0.00279	CcSEcCtD
Methadone—Weight decreased—Docetaxel—skin cancer	0.000427	0.00279	CcSEcCtD
Methadone—Anorexia—Dactinomycin—skin cancer	0.000425	0.00278	CcSEcCtD
Methadone—Rash—Imiquimod—skin cancer	0.000424	0.00277	CcSEcCtD
Methadone—CYP19A1—female reproductive system—skin cancer	0.000424	0.0179	CbGeAlD
Methadone—Dermatitis—Imiquimod—skin cancer	0.000424	0.00277	CcSEcCtD
Methadone—OPRM1—head—skin cancer	0.000422	0.0178	CbGeAlD
Methadone—Headache—Imiquimod—skin cancer	0.000422	0.00275	CcSEcCtD
Methadone—Anxiety—Temozolomide—skin cancer	0.000419	0.00274	CcSEcCtD
Methadone—Decreased appetite—Bleomycin—skin cancer	0.000416	0.00271	CcSEcCtD
Methadone—Dry mouth—Temozolomide—skin cancer	0.000411	0.00269	CcSEcCtD
Methadone—Pain—Bleomycin—skin cancer	0.000409	0.00267	CcSEcCtD
Methadone—Confusional state—Temozolomide—skin cancer	0.000407	0.00266	CcSEcCtD
Methadone—Anaphylactic shock—Temozolomide—skin cancer	0.000403	0.00263	CcSEcCtD
Methadone—Oedema—Temozolomide—skin cancer	0.000403	0.00263	CcSEcCtD
Methadone—ABCB1—blood vessel—skin cancer	0.000403	0.017	CbGeAlD
Methadone—Nausea—Imiquimod—skin cancer	0.0004	0.00261	CcSEcCtD
Methadone—Thrombocytopenia—Temozolomide—skin cancer	0.000395	0.00258	CcSEcCtD
Methadone—Convulsion—Fluorouracil—skin cancer	0.000394	0.00258	CcSEcCtD
Methadone—Feeling abnormal—Bleomycin—skin cancer	0.000394	0.00257	CcSEcCtD
Methadone—Hyperhidrosis—Temozolomide—skin cancer	0.00039	0.00255	CcSEcCtD
Methadone—Decreased appetite—Dactinomycin—skin cancer	0.000388	0.00253	CcSEcCtD
Methadone—Anorexia—Temozolomide—skin cancer	0.000384	0.00251	CcSEcCtD
Methadone—Pain—Dactinomycin—skin cancer	0.000381	0.00249	CcSEcCtD
Methadone—Urticaria—Bleomycin—skin cancer	0.00038	0.00248	CcSEcCtD
Methadone—Body temperature increased—Bleomycin—skin cancer	0.000378	0.00247	CcSEcCtD
Methadone—Confusional state—Fluorouracil—skin cancer	0.000375	0.00245	CcSEcCtD
Methadone—Oedema—Fluorouracil—skin cancer	0.000372	0.00243	CcSEcCtD
Methadone—Anaphylactic shock—Fluorouracil—skin cancer	0.000372	0.00243	CcSEcCtD
Methadone—Feeling abnormal—Dactinomycin—skin cancer	0.000367	0.0024	CcSEcCtD
Methadone—Insomnia—Temozolomide—skin cancer	0.000365	0.00238	CcSEcCtD
Methadone—Gastrointestinal pain—Dactinomycin—skin cancer	0.000365	0.00238	CcSEcCtD
Methadone—Thrombocytopenia—Fluorouracil—skin cancer	0.000364	0.00238	CcSEcCtD
Methadone—Visual impairment—Docetaxel—skin cancer	0.000364	0.00238	CcSEcCtD
Methadone—Tachycardia—Fluorouracil—skin cancer	0.000363	0.00237	CcSEcCtD
Methadone—Somnolence—Temozolomide—skin cancer	0.000358	0.00234	CcSEcCtD
Methadone—CYP19A1—head—skin cancer	0.000354	0.015	CbGeAlD
Methadone—Anorexia—Fluorouracil—skin cancer	0.000354	0.00231	CcSEcCtD
Methadone—Abdominal pain—Dactinomycin—skin cancer	0.000352	0.0023	CcSEcCtD
Methadone—Body temperature increased—Dactinomycin—skin cancer	0.000352	0.0023	CcSEcCtD
Methadone—Hypersensitivity—Bleomycin—skin cancer	0.000352	0.0023	CcSEcCtD
Methadone—Decreased appetite—Temozolomide—skin cancer	0.000351	0.00229	CcSEcCtD
Methadone—Flushing—Docetaxel—skin cancer	0.00035	0.00229	CcSEcCtD
Methadone—CYP2B6—skin of body—skin cancer	0.000349	0.0147	CbGeAlD
Methadone—Hypotension—Fluorouracil—skin cancer	0.000347	0.00227	CcSEcCtD
Methadone—Constipation—Temozolomide—skin cancer	0.000345	0.00225	CcSEcCtD
Methadone—Pain—Temozolomide—skin cancer	0.000345	0.00225	CcSEcCtD
Methadone—Asthenia—Bleomycin—skin cancer	0.000343	0.00224	CcSEcCtD
Methadone—Chills—Docetaxel—skin cancer	0.000339	0.00221	CcSEcCtD
Methadone—Pruritus—Bleomycin—skin cancer	0.000338	0.00221	CcSEcCtD
Methadone—Arrhythmia—Docetaxel—skin cancer	0.000337	0.0022	CcSEcCtD
Methadone—Insomnia—Fluorouracil—skin cancer	0.000336	0.0022	CcSEcCtD
Methadone—Feeling abnormal—Temozolomide—skin cancer	0.000332	0.00217	CcSEcCtD
Methadone—Somnolence—Fluorouracil—skin cancer	0.00033	0.00216	CcSEcCtD
Methadone—Gastrointestinal pain—Temozolomide—skin cancer	0.00033	0.00215	CcSEcCtD
Methadone—Erythema—Docetaxel—skin cancer	0.000329	0.00215	CcSEcCtD
Methadone—Hypersensitivity—Dactinomycin—skin cancer	0.000328	0.00215	CcSEcCtD
Methadone—Decreased appetite—Fluorouracil—skin cancer	0.000323	0.00211	CcSEcCtD
Methadone—Urticaria—Temozolomide—skin cancer	0.00032	0.00209	CcSEcCtD
Methadone—Asthenia—Dactinomycin—skin cancer	0.00032	0.00209	CcSEcCtD
Methadone—Abdominal pain—Temozolomide—skin cancer	0.000319	0.00208	CcSEcCtD
Methadone—Body temperature increased—Temozolomide—skin cancer	0.000319	0.00208	CcSEcCtD
Methadone—Orphenadrine—SCN10A—skin cancer	0.000318	0.442	CrCbGaD
Methadone—Pain—Fluorouracil—skin cancer	0.000318	0.00208	CcSEcCtD
Methadone—Muscle spasms—Docetaxel—skin cancer	0.000316	0.00206	CcSEcCtD
Methadone—Feeling abnormal—Fluorouracil—skin cancer	0.000306	0.002	CcSEcCtD
Methadone—Diarrhoea—Dactinomycin—skin cancer	0.000305	0.00199	CcSEcCtD
Methadone—Vomiting—Bleomycin—skin cancer	0.000304	0.00199	CcSEcCtD
Methadone—CYP2C8—female reproductive system—skin cancer	0.000304	0.0128	CbGeAlD
Methadone—Rash—Bleomycin—skin cancer	0.000301	0.00197	CcSEcCtD
Methadone—Dermatitis—Bleomycin—skin cancer	0.000301	0.00197	CcSEcCtD
Methadone—Hypersensitivity—Temozolomide—skin cancer	0.000297	0.00194	CcSEcCtD
Methadone—Urticaria—Fluorouracil—skin cancer	0.000295	0.00193	CcSEcCtD
Methadone—Syncope—Docetaxel—skin cancer	0.000295	0.00192	CcSEcCtD
Methadone—Body temperature increased—Fluorouracil—skin cancer	0.000294	0.00192	CcSEcCtD
Methadone—Palpitations—Docetaxel—skin cancer	0.00029	0.0019	CcSEcCtD
Methadone—Asthenia—Temozolomide—skin cancer	0.000289	0.00189	CcSEcCtD
Methadone—Loss of consciousness—Docetaxel—skin cancer	0.000289	0.00189	CcSEcCtD
Methadone—Pruritus—Temozolomide—skin cancer	0.000285	0.00186	CcSEcCtD
Methadone—Convulsion—Docetaxel—skin cancer	0.000285	0.00186	CcSEcCtD
Methadone—Nausea—Bleomycin—skin cancer	0.000284	0.00185	CcSEcCtD
Methadone—Vomiting—Dactinomycin—skin cancer	0.000283	0.00185	CcSEcCtD
Methadone—CYP2B6—lymphoid tissue—skin cancer	0.000282	0.0119	CbGeAlD
Methadone—Rash—Dactinomycin—skin cancer	0.000281	0.00184	CcSEcCtD
Methadone—Diarrhoea—Temozolomide—skin cancer	0.000276	0.0018	CcSEcCtD
Methadone—Hypersensitivity—Fluorouracil—skin cancer	0.000274	0.00179	CcSEcCtD
Methadone—Dry mouth—Docetaxel—skin cancer	0.000274	0.00179	CcSEcCtD
Methadone—CYP2B6—female reproductive system—skin cancer	0.000272	0.0115	CbGeAlD
Methadone—Confusional state—Docetaxel—skin cancer	0.00027	0.00177	CcSEcCtD
Methadone—CYP2C9—female reproductive system—skin cancer	0.00027	0.0114	CbGeAlD
Methadone—Anaphylactic shock—Docetaxel—skin cancer	0.000268	0.00175	CcSEcCtD
Methadone—Oedema—Docetaxel—skin cancer	0.000268	0.00175	CcSEcCtD
Methadone—Dizziness—Temozolomide—skin cancer	0.000267	0.00174	CcSEcCtD
Methadone—Nausea—Dactinomycin—skin cancer	0.000265	0.00173	CcSEcCtD
Methadone—Shock—Docetaxel—skin cancer	0.000264	0.00172	CcSEcCtD
Methadone—Pruritus—Fluorouracil—skin cancer	0.000263	0.00172	CcSEcCtD
Methadone—Thrombocytopenia—Docetaxel—skin cancer	0.000263	0.00172	CcSEcCtD
Methadone—Tachycardia—Docetaxel—skin cancer	0.000262	0.00171	CcSEcCtD
Methadone—Vomiting—Temozolomide—skin cancer	0.000256	0.00167	CcSEcCtD
Methadone—Anorexia—Docetaxel—skin cancer	0.000256	0.00167	CcSEcCtD
Methadone—Rash—Temozolomide—skin cancer	0.000254	0.00166	CcSEcCtD
Methadone—Diarrhoea—Fluorouracil—skin cancer	0.000254	0.00166	CcSEcCtD
Methadone—Dermatitis—Temozolomide—skin cancer	0.000254	0.00166	CcSEcCtD
Methadone—Headache—Temozolomide—skin cancer	0.000253	0.00165	CcSEcCtD
Methadone—Hypotension—Docetaxel—skin cancer	0.000251	0.00164	CcSEcCtD
Methadone—CYP19A1—lymph node—skin cancer	0.000248	0.0105	CbGeAlD
Methadone—Dizziness—Fluorouracil—skin cancer	0.000246	0.00161	CcSEcCtD
Methadone—Insomnia—Docetaxel—skin cancer	0.000243	0.00158	CcSEcCtD
Methadone—Oxaprozin—PTGS2—skin cancer	0.000241	0.336	CrCbGaD
Methadone—Nausea—Temozolomide—skin cancer	0.00024	0.00156	CcSEcCtD
Methadone—Somnolence—Docetaxel—skin cancer	0.000238	0.00156	CcSEcCtD
Methadone—Vomiting—Fluorouracil—skin cancer	0.000236	0.00154	CcSEcCtD
Methadone—Rash—Fluorouracil—skin cancer	0.000234	0.00153	CcSEcCtD
Methadone—Dermatitis—Fluorouracil—skin cancer	0.000234	0.00153	CcSEcCtD
Methadone—Decreased appetite—Docetaxel—skin cancer	0.000233	0.00152	CcSEcCtD
Methadone—Headache—Fluorouracil—skin cancer	0.000233	0.00152	CcSEcCtD
Methadone—Pain—Docetaxel—skin cancer	0.000229	0.0015	CcSEcCtD
Methadone—Constipation—Docetaxel—skin cancer	0.000229	0.0015	CcSEcCtD
Methadone—CYP2B6—head—skin cancer	0.000228	0.00961	CbGeAlD
Methadone—Feeling abnormal—Docetaxel—skin cancer	0.000221	0.00144	CcSEcCtD
Methadone—Nausea—Fluorouracil—skin cancer	0.000221	0.00144	CcSEcCtD
Methadone—Gastrointestinal pain—Docetaxel—skin cancer	0.000219	0.00143	CcSEcCtD
Methadone—Body temperature increased—Docetaxel—skin cancer	0.000212	0.00138	CcSEcCtD
Methadone—Abdominal pain—Docetaxel—skin cancer	0.000212	0.00138	CcSEcCtD
Methadone—CYP3A4—female reproductive system—skin cancer	0.000206	0.00869	CbGeAlD
Methadone—CYP2D6—female reproductive system—skin cancer	0.000202	0.00855	CbGeAlD
Methadone—Hypersensitivity—Docetaxel—skin cancer	0.000198	0.00129	CcSEcCtD
Methadone—ABCB1—epithelium—skin cancer	0.000196	0.00828	CbGeAlD
Methadone—Asthenia—Docetaxel—skin cancer	0.000192	0.00126	CcSEcCtD
Methadone—Pruritus—Docetaxel—skin cancer	0.00019	0.00124	CcSEcCtD
Methadone—Diarrhoea—Docetaxel—skin cancer	0.000183	0.0012	CcSEcCtD
Methadone—Dizziness—Docetaxel—skin cancer	0.000177	0.00116	CcSEcCtD
Methadone—Vomiting—Docetaxel—skin cancer	0.00017	0.00111	CcSEcCtD
Methadone—ABCB1—mammalian vulva—skin cancer	0.00017	0.00718	CbGeAlD
Methadone—CYP2D6—head—skin cancer	0.000169	0.00714	CbGeAlD
Methadone—Rash—Docetaxel—skin cancer	0.000169	0.0011	CcSEcCtD
Methadone—Dermatitis—Docetaxel—skin cancer	0.000169	0.0011	CcSEcCtD
Methadone—Headache—Docetaxel—skin cancer	0.000168	0.0011	CcSEcCtD
Methadone—Phenylbutazone—PTGS2—skin cancer	0.000159	0.222	CrCbGaD
Methadone—Nausea—Docetaxel—skin cancer	0.000159	0.00104	CcSEcCtD
Methadone—ABCB1—lymphoid tissue—skin cancer	0.000151	0.00637	CbGeAlD
Methadone—ABCB1—female reproductive system—skin cancer	0.000146	0.00615	CbGeAlD
Methadone—ABCB1—head—skin cancer	0.000122	0.00514	CbGeAlD
Methadone—ABCB1—lymph node—skin cancer	8.52e-05	0.0036	CbGeAlD
